Beyond atezolizumab plus bevacizumab in patients with advanced hepatocellular carcinoma: overall efficacy and safety of tyrosine kinase inhibitors in a real-world setting
Background: In patients with advanced hepatocellular carcinoma (HCC) progressing after atezolizumab and bevacizumab, the optimal therapeutic sequence is still unclear and no second-line agent has proven its efficacy. Objectives: The aim of this retrospective multicenter real-world cohort study was t...
Salvato in:
| Autori principali: | , , , , , , , , , , , , |
|---|---|
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
SAGE Publishing
2023-08-01
|
| Serie: | Therapeutic Advances in Medical Oncology |
| Accesso online: | https://doi.org/10.1177/17588359231189425 |
| Tags: |
Nessun Tag, puoi essere il primo ad aggiungerne!!
|